|Free Dividend Report|
|Stock Splits Calendar|
|AEMD Stock Split History|
|Preferred Stock Newsletter|
|Top Option Ideas|
|Stock Message Boards|
Aethlon Medical (AEMD) has 1 split in our AEMD split history database. The split for AEMD took place on October 15, 2019. This was a 1 for 15 reverse split, meaning for each 15 shares of AEMD owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 66.6666666666667 share position following the split.
When a company such as Aethlon Medical conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the AEMD split history from start to finish, an original position size of 1000 shares would have turned into 66.6666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Aethlon Medical shares, starting with a $10,000 purchase of AEMD, presented on a split-history-adjusted basis factoring in the complete AEMD split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-6.50%|
|About Aethlon Medical|
|Aethlon Medical is a medical technology company. The Aethlon Hemopurifier® is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. In cancer, the Hemopurifier depletes the presence of circulating tumor-derived exosomes that promote immune suppression, seed the spread of metastasis and inhibit the benefit of cancer therapies. Co. is also the majority owner of Exosome Sciences, Inc. (ESI), a company focused on the discovery of exosomal biomarkers to diagnose and monitor life-threatening diseases. ESI develops TauSome biomarker candidate to diagnose chronic traumatic encephalopathy in the living. According to our AEMD split history records, Aethlon Medical has had 1 split.|
|AEMD Split History Table|
|10/15/2019||1 for 15|
|Healthcare Stock Splits|
|AEMD is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:
Also explore: AEMD shares outstanding history